202 related articles for article (PubMed ID: 30223539)
21. Country-specific approaches to latent tuberculosis screening targeting migrants in EU/EEA* countries: A survey of national experts, September 2019 to February 2020.
Margineanu I; Rustage K; Noori T; Zenner D; Greenaway C; Pareek M; Akkerman O; Hayward S; Friedland JS; Goletti D; Stienstra Y; Hargreaves S;
Euro Surveill; 2022 Mar; 27(12):. PubMed ID: 35332865
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis B and C surveillance and screening programmes in the non-EU/EEA Member States of the WHO European Region: survey findings from 10 countries, 2012.
Mozalevskis A; Eramova I; Safreed-Harmon K; Lazarus JV
Euro Surveill; 2016 Jun; 21(22):. PubMed ID: 27277421
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of direct-acting antivirals for chronic hepatitis C treatment in migrant and non-migrant populations in France.
Djaogol T; Fontaine H; Baudoin M; Protopopescu C; Marcellin F; Dorival C; Simony M; Petrov-Sanchez V; Bourlière M; Delarocque-Astagneau E; Pol S; Carrat F; Carrieri P;
Liver Int; 2021 Oct; 41(10):2328-2340. PubMed ID: 33590608
[TBL] [Abstract][Full Text] [Related]
24. Strengthening screening for infectious diseases and vaccination among migrants in Europe: What is needed to close the implementation gaps?
Noori T; Hargreaves S; Greenaway C; van der Werf M; Driedger M; Morton RL; Hui C; Requena-Mendez A; Agbata E; Myran DT; Pareek M; Campos-Matos I; Nielsen RT; Semenza J; Nellums LB; Pottie K;
Travel Med Infect Dis; 2021; 39():101715. PubMed ID: 32389827
[TBL] [Abstract][Full Text] [Related]
25. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*.
Hatzakis A; Wait S; Bruix J; Buti M; Carballo M; Cavaleri M; Colombo M; Delarocque-Astagneau E; Dusheiko G; Esmat G; Esteban R; Goldberg D; Gore C; Lok AS; Manns M; Marcellin P; Papatheodoridis G; Peterle A; Prati D; Piorkowsky N; Rizzetto M; Roudot-Thoraval F; Soriano V; Thomas HC; Thursz M; Valla D; van Damme P; Veldhuijzen IK; Wedemeyer H; Wiessing L; Zanetti AR; Janssen HL
J Viral Hepat; 2011 Sep; 18 Suppl 1():1-16. PubMed ID: 21824223
[TBL] [Abstract][Full Text] [Related]
26. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
27. A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA.
Vroling H; Oordt-Speets AM; Madeddu G; Babudieri S; Monarca R; O'Moore E; Vonk Noordegraaf-Schouten M; Wolff H; Montanari M; Hedrich D; Tavoschi L
J Viral Hepat; 2018 Dec; 25(12):1406-1422. PubMed ID: 30187607
[TBL] [Abstract][Full Text] [Related]
28. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.
Hahné SJ; Veldhuijzen IK; Wiessing L; Lim TA; Salminen M; Laar Mv
BMC Infect Dis; 2013 Apr; 13():181. PubMed ID: 23597411
[TBL] [Abstract][Full Text] [Related]
29. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
[TBL] [Abstract][Full Text] [Related]
30. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?
Ioannou GN; Feld JJ
Gastroenterology; 2019 Jan; 156(2):446-460.e2. PubMed ID: 30367836
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups.
Falla AM; Hofstraat SHI; Duffell E; Hahné SJM; Tavoschi L; Veldhuijzen IK
BMC Infect Dis; 2018 Feb; 18(1):79. PubMed ID: 29433454
[TBL] [Abstract][Full Text] [Related]
32. Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review.
Hofstraat SHI; Falla AM; Duffell EF; Hahné SJM; Amato-Gauci AJ; Veldhuijzen IK; Tavoschi L
Epidemiol Infect; 2017 Oct; 145(14):2873-2885. PubMed ID: 28891457
[TBL] [Abstract][Full Text] [Related]
33. Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents.
Olafsson S; Tyrfingsson T; Runarsdottir V; Bergmann OM; Hansdottir I; Björnsson ES; Johannsson B; Sigurdardottir B; Fridriksdottir RH; Löve A; Hellard M; Löve TJ; Gudnason T; Heimisdottir M; Gottfredsson M
J Intern Med; 2018 May; 283(5):500-507. PubMed ID: 29512219
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA: A systematic review.
Mason LMK; Veldhuijzen IK; Duffell E; van Ahee A; Bunge EM; Amato-Gauci AJ; Tavoschi L
J Viral Hepat; 2019 Dec; 26(12):1431-1453. PubMed ID: 31332919
[TBL] [Abstract][Full Text] [Related]
35. Securing wider EU commitment to the elimination of hepatitis C virus.
Wedemeyer H; Tergast TL; Lazarus JV; Razavi H; Bakoyannis K; Baptista-Leite R; Bartoli M; Bruggmann P; Buşoi CS; Buti M; Carballo M; Castera L; Colombo M; Coutinho RS; Dadon Y; Esmat G; Esteban R; Farran JC; Gillyon-Powell M; Goldberg D; Hutchinson S; Janssen HLA; Kalamitsis G; Kondili LA; Lambert JS; Marinho RT; Maticic M; Patricello A; Peck-Radosavljevic M; Pol S; Poljak M; Pop C; Sokol T; Sypsa V; Tözün N; Younossi Z; Aghemo A; Papatheodoridis GV; Hatzakis A
Liver Int; 2023 Feb; 43(2):276-291. PubMed ID: 36196744
[TBL] [Abstract][Full Text] [Related]
36. [The impact of direct-acting antiviral therapy on the diagnosis of hepatitis-C virus-associated hepatocellular carcinoma].
Takahashi A; Shima T; Kinoshita N; Yano K; Ueno T; Nishiwaki M; Yamamoto Y; Oya H; Amano I; Matsumoto J; Mitsumoto Y; Tanaka I; Sakai K; Sawai N; Mizuno C; Mizuno M; Itoh Y; Okanoue T
Nihon Shokakibyo Gakkai Zasshi; 2018; 115(2):184-194. PubMed ID: 29459562
[TBL] [Abstract][Full Text] [Related]
37. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of a screening program for HBV, HCV, and HIV infections in African migrants to Sicily.
Prestileo T; Di Marco V; Dino O; Sanfilippo A; Tutone M; Milesi M; Di Marco L; Picchio CA; Craxì A; Lazarus JV;
Dig Liver Dis; 2022 Jun; 54(6):800-804. PubMed ID: 34649829
[TBL] [Abstract][Full Text] [Related]
39. Universal screening for hepatitis C - in for a penny, in for a pound.
Garrido I; Macedo G
Eur J Clin Microbiol Infect Dis; 2022 Mar; 41(3):341-347. PubMed ID: 35022892
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations.
Coward S; Leggett L; Kaplan GG; Clement F
BMJ Open; 2016 Sep; 6(9):e011821. PubMed ID: 27601496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
